HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 5, Pages e1065369
Publisher
Informa UK Limited
Online
2015-07-02
DOI
10.1080/2162402x.2015.1065369
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- SOX2 Expression and Prognostic Significance in Ovarian Carcinoma
- (2013) Deborah L. Pham et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Cancer classification using the Immunoscore: a worldwide task force
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2
- (2012) Margit H. Lampen et al. MOLECULAR IMMUNOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
- (2011) Osama E. Rahma et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer
- (2011) M. A. Morse et al. CLINICAL CANCER RESEARCH
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin
- (2010) Akiko Hayashi et al. INTERNATIONAL JOURNAL OF CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission
- (2008) C. S.M. Diefenbach et al. CLINICAL CANCER RESEARCH
- Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues
- (2008) Ke Long Jin et al. Journal of Gynecologic Oncology
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
- (2007) Markéta Tomšová et al. GYNECOLOGIC ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now